Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Trevena Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TRVN
Nasdaq
8731
https://www.trevena.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Trevena Inc
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
- Apr 1st, 2024 11:00 am
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
- Dec 28th, 2023 7:00 pm
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
- Dec 27th, 2023 2:10 pm
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
- Dec 4th, 2023 12:02 pm
Trevena Awarded OLINVYK Agreement with Premier, Inc.
- Dec 4th, 2023 12:00 pm
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
- Nov 30th, 2023 12:00 pm
Trevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 17th, 2023 10:06 am
Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript
- Nov 15th, 2023 8:08 pm
Trevena Reports Third Quarter 2023 Results and Provides Business Update
- Nov 14th, 2023 12:00 pm
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
- Nov 9th, 2023 12:00 pm
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
- Oct 16th, 2023 11:00 am
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
- Oct 2nd, 2023 11:00 am
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
- Sep 6th, 2023 11:01 am
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
- Sep 6th, 2023 11:00 am
Trevena Reports Second Quarter 2023 Results and Provides Business Update
- Aug 14th, 2023 11:00 am
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
- Jul 20th, 2023 11:00 am
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
- Jun 26th, 2023 11:00 am
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
- May 31st, 2023 11:00 am
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
- May 30th, 2023 11:00 am
Q1 2023 Trevena Inc Earnings Call
- May 16th, 2023 1:01 am
Scroll